Business
Adial is developing AD04 as a genetically targeted therapy candidate for alcohol use disorder.
Adial reduced losses and improved equity, but AD04 remains pre-revenue with a going-concern warning.
The read at a glance✓ Audited against SEC data
- Business mix — AD04 for alcohol use disorderNote
- Revenue — No revenue in local bundleNote
- Profitability — Net loss improved to $8.0MOK
- Cash burn — Cash from operations improved to -$6.5MOK
- Balance sheet — Equity +29.7% to $5.3MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Going-concern warningWatch
Leadership changes
From ADIAL PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Vinay Shah · Chief Financial Officer · appointmenteff. 2024-11-16
- Bankole A. Johnson · departureeff. 2024-05-17
- Matthew Davidson · President · appointment
Latest filings
- 8-K · Company announcement2026-08-25
- DEF 14A · Annual proxy (pay & governance)2026-08-24
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-17
- 10-Q · Quarterly report2026-08-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ADIAL PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.